Pharmacokinetics of pafenolol in the rat: A suitable model for studying absorption mechanisms of a drug exhibiting unusual absorption properties in man
- 1 October 1990
- journal article
- research article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 11 (7) , 619-631
- https://doi.org/10.1002/bdd.2510110707
Abstract
The pharmacokinetics of pafenolol, a highly selective β1‐adrenoceptor antagonist, have been studied in starved and unstarved rats. Separate groups received intravenous doses (0·3 and 3·0 μmol kg−1) and oral doses (1 and 25 μmol kg−1). The systemic clearance of pafenolol was constant in the dose range investigated where the absolute oral bioavailability increased from 15 to 27 per cent in the starved and from 9·1 to 21 per cent in the unstarved rats, when the oral dose was raised from 1 to 25 μmol kg−1. The blood concentration profile after an oral solution of pafenolol exhibited two peaks in the majority of the rats. The major part of the absorption was associated with the second peak which appeared about 4 h after dosing in both starved and unstarved rats. Food lowered the degree of bioavailability and shifted the t, to about 1 hour compared to half an hour in starved rats. The low bioavailability was primarily due to incomplete uptake from the gastrointestinal tract. Our study shows that pafenolol is absorbed in a similar way to that in man. The mechanisms behind the dose‐dependent bioavailability and the two peaks in the absorption profile after an oral solution will be further explained in the rat.Keywords
This publication has 25 references indexed in Scilit:
- On the dose dependency of Cyclosporin a absorption and disposition in healthy volunteersJournal of Pharmacokinetics and Biopharmaceutics, 1988
- The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenonJournal of Pharmacokinetics and Biopharmaceutics, 1987
- A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: A double-site model for drug absorptionJournal of Pharmacokinetics and Biopharmaceutics, 1987
- Intestinal absorption of a .BETA.-adrenergic blocking agent nadolol. I Comparison of absorption behavior of nadolol with those of other .BETA.-blocking agents in rats.CHEMICAL & PHARMACEUTICAL BULLETIN, 1986
- Intestinal absorption of a .BETA.-adrenergic blocking agent nadolol. II Mechanism of the inhibitory effect on the intestinal absorption of nadolol by sodium cholate in rats.CHEMICAL & PHARMACEUTICAL BULLETIN, 1985
- Monitoring 24-hour blood pressure in a drug trial. Evaluation of a noninvasive device.Hypertension, 1985
- First-Pass EliminationClinical Pharmacokinetics, 1984
- The effects of pafenolol and metoprolol on ventilatory function and haemodynamics during exercise by asthmatic patientsEuropean Journal of Clinical Pharmacology, 1983
- Pharmacokinetic interpretation of the enterohepatic recirculation and first-pass elimination of morphine in the ratJournal of Pharmacokinetics and Biopharmaceutics, 1978
- Preliminary trial of aminoglutethimide in breast cancerCancer, 1973